News | August 16, 2021
Glenmark Pharmaceuticals net profit at Rs 306.52 crores in Q1FY22
The company reports revenue growth of 26% and PAT growth of 21% YoY
The company reports revenue growth of 26% and PAT growth of 21% YoY
This therapy may provide the first potential oral treatment for COVID-19, recognizing the global emergency of new SARS-CoV-2 variants
The acquisition will provide it with a foothold in the US $ 48 billion global animal health market
It strengthens Syngene’s portfolio as a fully integrated custom biomanufacturer with added mammalian and microbial capabilities for clinical and commercial supplies
Winlevi, the recently added anti-acne product with a new mechanism of action and broad-based use (vs Absorica), will further boost the derma portfolio and Speciality business growth
Domestic formulations business records 39 % growth while the international business revenue was largely flat as compared to Q1 FY21
Demand normalisation post the second wave contributed to the steady growth
Anti-malaria API facility will be operational in 15-18 months
The company has strong product launches both in India and overseas
TSC causes epilepsy in up to 85 % of patients, and up to 60 % of those patients do not respond to standard anti-seizure medicines
Subscribe To Our Newsletter & Stay Updated
